Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme.

J. G. Johnson, W. D. Black, R. A. Vukovich, F. E. Hatch, B. I. Friedman, C. F. Blackwell, A. N. Shenouda, L. Share, R. E. Shade, S. R. Acchiardo, E. E. Muirhead

    Research output: Contribution to journalArticlepeer-review

    26 Scopus citations


    1. The results of the administration of the nona-peptide inhibitor (SQ 20,881) of the enzymatic conversion of angiotensin I into angiotensin II in twelve severe hypertensive patients are presented. 2. Administration of the compound was associated with a fall in blood pressure in ten of twelve patients. 3. Four patients had a normal plasma renin activity (PRA) with a range of 1.6-3.7 ng h-1 ml-1 and eight patients had a high PRA with a range of 5.0-74 ng h-1 ml-1. Two of the patients with normal PRA had no fall in blood pressure despite receiving 2 mg/kg of the compound. Two patients with normal PRA, however, did respond, thus indicating that a high PRA is not necessary for a response to the inhibitor compound. 4. It was found that haemodialysis or diuresis with frusemide enhanced the blood pressure response to the compound. 5. The presence of a measured low total blood volume was found to be associated with an exaggerated fall in blood pressure to a small dose of compound (0.125 mg/kg) in one patient.

    Original languageEnglish (US)
    Pages (from-to)53s-56s
    JournalClinical science and molecular medicine. Supplement
    StatePublished - Jun 1 1975

    ASJC Scopus subject areas

    • Medicine(all)


    Dive into the research topics of 'Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme.'. Together they form a unique fingerprint.

    Cite this